A trial of three antiretroviral regimens in HIV-1-infected children

New England Journal of Medicine

Volumn 350, Issue 24, 2004, Pages 2471-2480

  Luzuriaga, Katherine ^a   McManus, Margaret ^a   Mofenson, Lynne ^b   Britto, Paula ^c   Graham, Bobbie ^d   Sullivan, John L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ANTIRETROVIRUS AGENT;

AGE; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; TIME; ANTIBIOTIC RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; DRUG EFFECT; GENETICS; MUTATION; PHYSIOLOGY; PRESCHOOL CHILD; STATISTICAL MODEL; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LOGISTIC MODELS; MALE; MUTATION; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 2942625676     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa032706     Document Type: Article

References (13)

1. Ho DD. Dynamics of HIV-1 replication in vivo. J Clin Invest 1997;99:2565-7.
2. Luzuriaga K, Wu HL, McManus M, et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol 1999;73:362-7.
3. Abrams EJ, Kuhn L. Should treatment be started among all HIV-infected children and then stopped? Lancet 2003;362:1595-6.
4. Gray L, Newell ML, Thorne C, Peckham C, Levy J. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001;108:116-22.
5. Diaz C, Hanson C, Cooper ER, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:221-8.
6. Spira R, Lepage P, Msellati P, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Pediatrics 1999;104:1118-9. abstract.
7. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003;362:1605-11.
8. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis 1997;176:118-25.
9. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, Md.: AIDSinfo, February 4, 2002. (Accessed May 14, 2004, at http:// aidsinfo.nih.gov/guidelines/archive.asp.)
10. Abrams EJ, Wiener J, Carter R, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003;17:867-77.
11. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Rockville, Md.: AIDSinfo, June 25, 2003. (Accessed May 14, 2004, at http://aidsinfo.nih.gov/ guidelines/archive.asp.)
12. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med 2002;3:215-26.
13. Hainaut M, Peltier CA, Gerard M, Marissens D, Zissis G, Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr 2000;159:778-82.